Andrew Blauvelt, MD

Are IL-23 inhibitors, rather than IL-17 inhibitors, the preferred biologic for psoriasis patients at risk of developing psoriatic arthritis?

Blauvelt discusses studies revealing that disease severity, injection frequency, pain, and geography all shape treatment preferences.

Phase 3 ONWARD data for the investigational TYK2 inhibitor envudeucitinib join a rapidly crowding oral psoriasis space.

Blauvelt discussed highlights from the phase 3 ONWARD1 and ONWARD2 clinical trials presented at AAD 2026.

Andrew Blauvelt, MD, discusses switching therapies for atopic dermatitis (AD) treatment.

Andrew Blauvelt, MD, discusses upadacitinib for the treatment of atopic dermatitis (AD).

A dermatology expert discusses taking a nuanced approach to interpreting the boxed warnings for JAK inhibitor for atopic dermatitis (AD) treatment.

An expert discusses treatment selection for atopic dermatitis (AD) based on short and long-term data.

Andrew Blauvelt, MD, provides an overview of the significance of JAK/Stat pathway inhibition in targeting the pathophysiology of atopic dermatology (AD).

Andrew Blauvelt, MD, provides an overview of different treatment options that are available for patients with moderate to severe atopic dermatitis (AD).